Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 4 ans
A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
(1) After 30 weeks, to assess the effect of the addition of sitagliptin compared with glimepiride on HbA1c. (2) To assess the safety and the tolerability of sitagliptin compared with glimepiride.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Pharma GmbH (Germany)
MAJ Il y a 4 ans
Phase II sudy of cetuximab for the treatment of refractory or relapsed multiple myeloma Erbitux for Multiple MyelomA
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe and effective when compared to ertugliflozin alone and Sitagliptin alone in patients with Type 2 Diabetes whose sugar levels are not well controlled by their current treatment with Metaformin
In subjects with T2DM and inadequate glycemic control on metformin ≥1500 mg/day, after 26 weeks: 1. To assess the A1C-lowering efficacy of the addition of ertugliflozin 15 mg q.d. plus sitagliptin 10...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 4 ans
Estudio multicéntrico de 2 partes para evaluar la farmacocinética, la seguridad y la tolerabilidad del aprepitant en pacientes pediátricos sometidos a una intervención quirúrgica. A Multicenter, 2-Part Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery
To estimate postoperative aprepitant plasma concentration profiles and pharmacokinetic parameters (AUC0-48, Cmax, Tmax, C24 hr, and C48 hr) obtained from infants 6 months to < 2 years of age and child...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme
Entre 18 ans
et 99 ans
Merck Sharp & Dohme (MSD)
MAJ Il y a 4 ans
Étude KEYNOTE-641 : étude de phase 3, randomisée, en double aveugle, évaluant l'efficacité du pembrolizumab associé l'enzalutamide par rapport à un placebo associé à l'enzalutamide, chez des patients ayant un cancer de la prostate métastatique, résistant à la castration médicale (mCRPC).
MK3475-641 - A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cance...
Pays
France
Organes
Prostate
Spécialités
Immunothérapie - Vaccinothérapie
,
Hormonothérapie
Essai ouvert aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 4 ans
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk and not Adequately Controlled with Atorvastatin 20 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/40mg) versus Doubling the Baseline Dose to Atorvastatin 40 mg
In patients with primary hypercholesterolemia and high cardiovascular risk treated with atorvastatin 20 mg and with LDL-Cholesterol blood level (LDL-C) ≥ 100 mg/dl (2.59 mmol/L) and ≤ 160 mg/dl (4.14 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 4 ans
A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection Ensayo Clínico en fase II para estudiar la eficacia y seguridad del régimen combinado de MK-5172 + MK-8742 + Ribavirina (RBV) en pacientes con infección crónica por el virus de la hepatitis C
In subjects with chronic HCV GT 1 infection who have failed prior DAA + PR treatment, with pre-treatment HCV RNA of at least 10,000 IU/mL: -To evaluate the efficacy of MK-5172 in combination with MK-8...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc
MAJ Il y a 4 ans
MK-3475 (pembrolizumab) in subjects with Classical Hodgkin Lymphoma
To determine the safety, tolerability and Overall Response Rate (ORR) of pembrolizumab in each of the three cohorts listed below. Cohort 1: Subjects with relapsed/refractory classical Hodgkin Lymp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck KGaA
MAJ Il y a 4 ans
Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing advanced NSCLC
To show superiority in terms of overall survival time of patients receiving platinum-based chemotherapy plus cetuximab as first-line treatment compared with patients receiving the same chemotherapy al...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck, Sharp & Dohme Ireland (Human Health) Limited
MAJ Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at Moderately High Risk and High Risk for CHD
To assess the percent change from baseline in LDL-C levels after 12 weeks of treatment at the usual start dose comparisons of ezetimibe/simvastatin 10/20 mg versus atorvastatin 10 mg, and ezetimibe/si...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant